ArticleJournal of preventive medicine and public health = Yebang Uihakhoe chi2026
Global, Regional, and National Burden of Heart Failure Attributable to Chronic Obstructive Pulmonary Disease From 1990 to 2021, With Projections to 2050.
Article in Journal of preventive medicine and public health = Yebang Uihakhoe chi, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Objectives: Heart failure (HF), a common comorbidity of chronic obstructive pulmonary disease (COPD), is associated with an increased risk of death among patients with COPD. However, no systematic assessment has quantified the population-level burden of comorbid COPD and HF, worldwide. This study assessed the global, regional, and national HF burden attributable to COPD from 1990 to 2021 and projected this burden to 2050. Methods: Data on the non-fatal burden of COPD-attributable HF, including prevalence and years lived with disability (YLDs), were obtained from the Global Burden of Disease Study 2021. Temporal trends in age-standardized rates (ASRs) for COPD-attributable HF from 1990 to 2021 were examined using joinpoint models. Bayesian age-period-cohort models were used to project ASRs to 2050. Results: From 1990 to 2021, the absolute numbers of prevalent cases and YLDs for COPD-attributable HF increased globally, and the ASRs for prevalence and YLDs also increased. These upward trends were projected to continue to 2050. The burden of HF attributable to COPD was consistently higher in males than in females and higher in older adults than in younger individuals. By severity level, the burden of HF attributable to COPD was mainly driven by the treated and severe subtypes of HF. The burden varied substantially across regions, with low-socio-demographic index regions had the highest age-standardized burden. Conclusions: The global non-fatal burden of HF attributable to COPD was substantial from 1990 to 2021 and may continue to increase to 2050. Public health interventions targeting HF attributable to COPD may help reduce this burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.